Abstracts tagged "Disease Activity and psoriatic arthritis"

Abstract Number: 674 • 2018 ACR/ARHP Annual Meeting
Defining the Therapeutic Target in Psoriatic Arthritis: MDA Versus Dapsa
Andrea Lujan Coronel Ale¹, Osvaldo Luis Cerda¹, Marina Natalia Fornaro², Carolina Ayelen Isnardi³, Emilce E Schneeberger⁴ and Gustavo Citera¹, ¹Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ²Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina, ³Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: T2T guidelines for psoriatic arthritis (PsA) propose using DAPSA or MDA to define the therapeutic target, but with differences in preference among experts. Objective:…
Abstract Number: 2551 • 2017 ACR/ARHP Annual Meeting
Comparison between Two Cut-Off Values of Disease Activity in Psoriatic Arthritis Index and Validation of Its Simplified Clinical Version in Patients with Psoriatic Arthritis
Osvaldo Luis Cerda¹, Emilce E Schneeberger¹, Cecilia Zaffarana¹, Andrea Lujan Coronel Ale¹, Marina Natalia Fornaro², Margarita Landi¹, Marcos Rosemffet¹, Fernando Dal Pra¹, Javier Rosa³ and Gustavo Citera⁴, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, buenos aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁴Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: Two groups established cut-off values for Disease Activity Index for Psoriatic Arthritis (DAPSA)1-2. The clinical DAPSA (cDAPSA) excludes CRP from its calculation and the…
Abstract Number: 2541 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
Jeanie Z. Fei¹, Justine (Yang) Ye¹, Anthony V. Perruccio², Dafna D Gladman³ and Vinod Chandran⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: PASS is the highest level of symptoms beyond which patients consider themselves well. Psoriatic Arthritis Disease Activity Score (PASDAS) is a recently developed composite…
Abstract Number: 2543 • 2017 ACR/ARHP Annual Meeting
Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Johannes H. L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, J.M.W. Hazes² and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Sint Franciscus Vlietland Group, Schiedam, Netherlands, ⁵Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: Presence of Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) is determined using a patient Visual Analogue Scale (VAS) global PsA activity and VAS…
Abstract Number: 1580 • 2014 ACR/ARHP Annual Meeting
Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort
Soumya M. Reddy¹, Jose U. Scher¹, Christopher Swearingen² and Yusuf Yazici¹, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose: Routine care cohorts can provide data about patient phenotypes, treatment choices and responses in the 'real world'. Studying the true impact of psoriatic arthritis…
Abstract Number: 341 • 2013 ACR/ARHP Annual Meeting
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Arthur Kavanaugh¹, Iain B. McInnes², Philip J. Mease³, Gerald G. Krueger⁴, Dafna D. Gladman⁵, Stephen Xu⁶, Linda Tang⁷ and Katrien van Beneden⁸, ¹University of California, San Diego, La Jolla, CA, ²Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁴School of Medicine, University of Utah, Salt Lake City, UT, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Janssen Research & Development, LLC., Horsham, PA, ⁸Janssen Biologics Europe, Leiden, Netherlands
Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: Results from 5 years of the long term extension of a randomized, placebo-controlled,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].